Ex-Axovant crew at Arvelle ups Series A haul, deploying $200M-plus to commercialize epilepsy drug in Europe
One of the characteristic features of the sprawling biotech group Vivek Ramaswamy has built at Roivant is its ability to whip up big-money financing deals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.